This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tsolaki, M. Articles by Kazis, A. Search for Related Content PubMed Articles by Tsolaki, M. Articles by Kazis, A. Social Bookmarking                         What's this?

Monotherapy with Lamotrigine in patients with Alzheimer's disease and seizures

Aristotle University of Thessaloniki, Macedonia, Greece

Anastasios Kourtis, MD

Psychiatric Hospital of Thessaloniki, Macedonia, Greece

Daniel Divanoglou, MD

3rd Department of Neurology, Psychiatric Hospital of Thessaloniki, Macedonia, Greece

Maria Bostanzopoulou, MD

Aristotle University of Thessaloniki, Macedonia, Greece

Aristides Kazis, MD

3rd Department of Neurology, Aristotle University of Thessaloniki, Macedonia, Greece

We used Lamotrigine LTG (50-600mg /24h) in 12 patients, 58-to 95-years-old (A Group) and other antiepileptics in nine patients (B Group) with the diagnosis of probable Alzheimer's disease (AD) and seizures. We also administered LTG (50-700mg/24h) in 16 patients (C Group) and other antiepileptics in nine patients (D Group) with other neurological disorders with cognitive disorders and seizures. The results showed that in eight from 12 patients with AD, and in nine from 16 with other neurological disorders, seizures stopped after treatment with LTG—while in five from nine patients with AD and six from 18 with other neurological disorders, seizures stopped after treatment with other antiepileptic drugs. Side effects in 28 patients treated with LTG included only three mild rashes, while side effects in 18 patients treated with other antiepileptic drugs included—six patients with fatigue, two with rashes, one with dizziness, one with low platelets, one with sleepiness and one with loss of hair. Conclusively, this study shows that LTG is an effective and safe monotherapy in patients with cognitive disorders and AD.

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 15, No. 2, 74-79 (2000)
DOI: 10.1177/153331750001500209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?